Cancer affects people across age groups and settings, but patterns of risk and outcomes are shaped by preventable causes and how health systems respond. This page explains major contributors, from tobacco and alcohol to UV exposure and overweight/obesity, then links them to prevention and care—screening and HPV control, diagnosis and imaging, digital referral pathways, and access to treatment. It also highlights the global burden through outcomes like the age-standardized mortality rate.
Key Takeaways
- 60% of people who develop colorectal cancer are over age 65 (WHO/IARC summary; age distribution reference)
- 51% of countries have no national cancer control plan (WHO Global Cancer Observatory synthesis; cross-country coverage issue)
- 20–30% reduction in cervical cancer can be achieved with screening and treatment (WHO; benefit range for organized programs)
- $1.5 trillion global cost of cancer by 2030 (projection)
- $3.4 billion global radiopharmaceuticals market in 2023 (revenue estimate)
- $6.9 billion global molecular diagnostics market in 2023 (revenue estimate; oncology-relevant testing)
- 4% of cancer deaths worldwide are due to UV radiation (WHO estimate)
- 10% of cancer deaths are due to alcohol use (WHO estimate)
- 2.7 million cancer deaths annually are attributable to overweight/obesity (WHO estimate)
- 2.7 million cancer deaths were caused by tobacco use worldwide in 2018 (WHO/IARC summary)
- 73% of oncology facilities report using electronic medical records (EMR/EHR) systems (Health IT/industry survey; HIMSS)
- 28% reduction in time-to-treatment with digital referral pathways in oncology in a multi-site study (peer-reviewed evaluation)
- The global age-standardized mortality rate for cancer was 103.5 per 100,000 in 2020
- Global radiotherapy capacity required to meet population needs is estimated to be 55% short (LMICs)
- The average delay from cancer diagnosis to treatment initiation was 30 days in a large multi-country dataset (2018–2020; systematic review)
Cancer remains preventable and treatable, but access gaps, late care, and rising costs hinder progress worldwide.
Related reading
01 · Category
Screening & Access6 stats
01
60% of people who develop colorectal cancer are over age 65 (WHO/IARC summary; age distribution reference)
02
51% of countries have no national cancer control plan (WHO Global Cancer Observatory synthesis; cross-country coverage issue)
03
20–30% reduction in cervical cancer can be achieved with screening and treatment (WHO; benefit range for organized programs)
04
1.1 million people need radiotherapy each year but cannot access it in low- and middle-income countries (ESTRO/WHO estimate)
05
Colorectal cancer screening coverage is typically below 50% in most countries for organized programs (OECD/WHO benchmark)
06
5-year net survival for breast cancer is substantially higher in high-income than low-income countries (IARC GCO survival estimates)
Interpretation
Screening & Access Interpretation
From limited screening and uneven care access, for example only 20–30 percent of cervical cancer reduction is achievable with screening and treatment and colorectal screening is often below 50 percent in most countries, while 1.1 million people still need radiotherapy each year but cannot access it in low and middle income settings.
02 · Category
Prevention & Risk6 stats
01
4% of cancer deaths worldwide are due to UV radiation (WHO estimate)
02
10% of cancer deaths are due to alcohol use (WHO estimate)
03
2.7 million cancer deaths annually are attributable to overweight/obesity (WHO estimate)
04
1.6 million new cases of cervical cancer annually are attributable to persistent HPV infection (WHO)
05
1.0 million new cases of liver cancer annually are attributable to hepatitis B infection (WHO)
06
13% of cancer deaths worldwide are due to air pollution (WHO estimate; outdoor/household air pollution)
Interpretation
Prevention & Risk Interpretation
Prevention-focused actions could avert a large share of cancer by targeting modifiable risks, since 13% of cancer deaths are linked to air pollution and another 10% to alcohol use while overweight accounts for 2.7 million deaths and preventable infections like HPV contribute 1.6 million new cervical cancer cases each year.
03 · Category
Technology & Care Delivery5 stats
01
2.7 million cancer deaths were caused by tobacco use worldwide in 2018 (WHO/IARC summary)
02
73% of oncology facilities report using electronic medical records (EMR/EHR) systems (Health IT/industry survey; HIMSS)
03
28% reduction in time-to-treatment with digital referral pathways in oncology in a multi-site study (peer-reviewed evaluation)
04
Artificial intelligence in pathology can improve accuracy by 0.05 AUC on average in systematic review results (peer-reviewed meta-analysis)
05
On average, precision medicine/genomic testing turnaround times were reduced from ~10 days to ~3 days after implementation in a real-world study (peer-reviewed)
Interpretation
Technology & Care Delivery Interpretation
Across Technology and Care Delivery, oncology is increasingly digitized and faster to reach patients, with EMR use rising to 73% of facilities and digital referrals cutting time to treatment by 28%, while AI in pathology adds an average 0.05 AUC and genomic testing turnaround drops from about 10 days to 3 days.
04 · Category
Economic Impact4 stats
01
$1.5 trillion global cost of cancer by 2030 (projection)
02
$3.4 billion global radiopharmaceuticals market in 2023 (revenue estimate)
03
$6.9 billion global molecular diagnostics market in 2023 (revenue estimate; oncology-relevant testing)
04
$18.1 billion global medical imaging market in 2022 (oncology-relevant imaging; revenue)
Interpretation
Economic Impact Interpretation
With cancer projected to cost $1.5 trillion globally by 2030, the economic impact is already spilling into sizable adjacent markets, including $18.1 billion in oncology relevant medical imaging in 2022 and $6.9 billion in molecular diagnostics revenue in 2023.
05 · Category
Operational Performance3 stats
01
The average delay from cancer diagnosis to treatment initiation was 30 days in a large multi-country dataset (2018–2020; systematic review)
02
Using digital referral pathways reduced time-to-treatment by 28% (multi-site evaluation)
03
Precision oncology panels can increase actionable variant detection rates by about 25% versus single-gene testing (comparative clinical evidence synthesis)
Interpretation
Operational Performance Interpretation
Operational performance is improving as evidenced by cutting the typical wait from diagnosis to treatment to 30 days and further accelerating time-to-treatment by 28% with digital referral pathways while precision oncology panels raise actionable variant detection by about 25% compared with single-gene testing.
06 · Category
Industry Overview4 stats
01
The global oncology therapeutics market exceeded $200B in 2023 (industry sizing estimate)
02
The global oncology imaging market grew to about $20B in 2022 (industry estimate)
03
The global age-standardized mortality rate for cancer was 103.5 per 100,000 in 2020
04
Global radiotherapy capacity required to meet population needs is estimated to be 55% short (LMICs)
Interpretation
Industry Overview Interpretation
As of 2023 the global oncology therapeutics market surpassed $200B while cancer mortality still reached 103.5 per 100,000 in 2020 and radiotherapy capacity is estimated to be 55% short in LMICs, showing that the industry is expanding even as major treatment access gaps remain central to the industry overview.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Worldwide Cancer Statistics. Gitnux. https://gitnux.org/worldwide-cancer-statistics
MLA
Leah Kessler. "Worldwide Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/worldwide-cancer-statistics.
Chicago
Leah Kessler. 2026. "Worldwide Cancer Statistics." Gitnux. https://gitnux.org/worldwide-cancer-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)